These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. Guerry MJ; Vanhille P; Ronco P; Debiec H Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779 [No Abstract] [Full Text] [Related]
5. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438 [No Abstract] [Full Text] [Related]
6. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. Seitz-Polski B; Debiec H; Rousseau A; Dahan K; Zaghrini C; Payré C; Esnault VLM; Lambeau G; Ronco P J Am Soc Nephrol; 2018 Feb; 29(2):401-408. PubMed ID: 29114041 [TBL] [Abstract][Full Text] [Related]
7. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report. Ishiwatari A; Wakai S; Shirakawa H; Honda K Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399 [TBL] [Abstract][Full Text] [Related]
8. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study. Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Medrano AS; Escalante EJ; Cáceres CC; Pamplona IA; Allende MT; Terrades NR; Carmeno NV; Roldán EO; Agudelo KV; Vasquez JJ Biomarkers; 2015 Feb; 20(1):77-83. PubMed ID: 25519165 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027 [TBL] [Abstract][Full Text] [Related]
11. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy. Li C; Li H; Wen YB; Li XM; Li XW BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581 [TBL] [Abstract][Full Text] [Related]
12. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?]. Netti GS; Ranieri E G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016 [TBL] [Abstract][Full Text] [Related]
13. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation. Anjum N; Nabi Z J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554 [TBL] [Abstract][Full Text] [Related]
14. [Membranous nephropathy: New insights in therapeutic approach]. Dahan K Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748 [TBL] [Abstract][Full Text] [Related]
15. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898 [TBL] [Abstract][Full Text] [Related]
16. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study. Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406 [TBL] [Abstract][Full Text] [Related]
17. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554 [TBL] [Abstract][Full Text] [Related]
18. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy. Chi JN; Lai TS; Wu CF; Fu TY; Chou YH; Chiu YL; Lin WC; Chiang WC; Chen YM; Wu MS J Formos Med Assoc; 2019 May; 118(5):898-906. PubMed ID: 30639075 [TBL] [Abstract][Full Text] [Related]
19. Can we manage without biopsy in membranous nephropathy with positive anti-PLA2R antibodies? Ruiz Martínez L; Fernández Fresnedo G; Rodrigo E; Heras M Nefrologia (Engl Ed); 2019; 39(3):311-312. PubMed ID: 30243493 [No Abstract] [Full Text] [Related]
20. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]